RemeGen Co., Ltd.
Status: Publicly traded
Direct answer
RemeGen Co., Ltd. is publicly traded on HKSE under the ticker 9995.HK.
RemeGen Co., Ltd. is a biopharmaceutical firm dedicated to the innovation, advancement, and marketing of biologic therapies. The company targets critical unmet medical requirements in autoimmune, oncological, and ophthalmic diseases within Mainland China and the United States. Its current offerings include Telitacicept (RC18), prescribed for the autoimmune condition systemic lupus erythematosus, and Disitamab...
Can you invest in RemeGen Co., Ltd.?
Yes. RemeGen Co., Ltd. trades publicly on HKSE as 9995.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for RemeGen Co., Ltd.
Detailed equity research is provided by MarketSnap.